Tuesday, 18 Dec 2018

You are here

NSAID Use Around Conception Increases Miscarriage Risk

A study from the American Journal of Obstetrics & Gynecology analyzed pregnant women from the Kaiser Permanente healthcare system and compared newly pregnant women who took non-steroidal anti-inflammatory drugs (NSAIDs) or acetaminophen or neither showed that using NSAIDs around conception carried a more than four-fold higher risk of early miscarriage. (Citation source: http://bit.ly/2tqNWN6)

While it is known that NSAIDs should be avoided after week 32 (to prevent premature closure of the ductus arteriosus), there are mixed messages regarding the use of NSAIDs during conception or early pregnancy.

They enrolled pregnant women (N=1,097) who were very early in pregnancy (median gestational age at enrollment was 39 days) to best ascertain fetal outcomes (including miscarriage.  Among eligible women contacted, 63% agreed to participate in the study.

NSAID use during pregnancy was associated with a significantly (59%) increased risk of miscarriage compared to either unexposed controls (adjusted hazard ratio (aHR)=1.59) or 45% increased risk if exposed to acetaminophen use (aHR=1.45). Nearly one-quarter of the women who took NSAIDs had miscarriages within the first 20 weeks of pregnancy, compared with 16 percent of women who took acetaminophen and 17 percent of women who took neither medication.

Most of this risk was evident for NSAID use around conception (aHR=1.89) with a statistically significant dose-response relationship (aHR=1.37) for NSAID use of 14 days or less (aHR=1.85) for NSAID use of 15 days or more.

The association was stronger for early miscarriage (<8 weeks gestational age): aHR=4.08 (95% CI: 2.25 to 7.41). Women with lower BMI (<25) appeared to be more susceptible to the effect of NSAID use around conception (aHR=3.78) than women with high BMI (≥25) (aHR=1.03).

NSAIDs are also among the most commonly used drugs by pregnant women.  These risk may be greater with longer NSAID use as women who used NSAIDs for two weeks or more had more miscarriages than those who took them for less time.

NSAID use around conception was associated with increased risk of miscarriage with a dose-response relationship, especially in women with a lower BMI.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

CDC Top 15 Most Common Opioid Overdose Drugs

The Dec. 12 issue of the National Vital Statistics Reports from the U.S. Centers for Disease Control and Prevention reports that the most commonly abused drugs causing drug overdose deaths (between 2011-2016) include fentanyl, heroin, oxycodone, and cocaine.

Trazodone High Risk of Falls and Fractures

The CMAJ (Canadian Medical Association Journal) has reported that trazadone use in the elderly may be associated with a risk of falls and major fractures. 

Using claims data from ICES, researchers compared 6588 seniors given trazadone to 2875 receiving another atypical antipsychotic.

Musculoskeletal Events with Statin Use

Analysis of the FDA Adverse Event Reporting System data examined the association between statins' musculoskeletal adverse events (MAEs).

Review of the data shows that atorvastatin and rosuvastatin (with strong low‐density lipoprotein cholesterol‐lowering effects) had a higher risk and a faster onset of MAEs when compared with simvastatin.

They could not detect whether concomitant drugs shifted the onset timing of MAEs. 

Low Short-Term Risks of NSAIDs in High Risk Patients

JAMA has published a large Canadian claims-based study showing that nonsteroidal anti-inflammatory drug (NSAID) use in patients with hypertension, heart failure, or chronic kidney disease was not associated with a significant safety risk - but this only looked at short-term outcomes (7-37 days of exposure). 

Update on Checkpoint Inhibitor Safety

“Autoimmunity is the Achilles heel of onco-immunotherapy” per Dr. Leonard Calabrese, which leaves a dilemma for rheumatologists. Onco-immunotherapy induces immune dysregulation to allow patients to develop an immune response to their cancer cells. An unfortunate side effect for patients taking onco-immunotherapy is often autoimmune-like diseases referred to as immune adverse reactions (irAEs). Studies in France and the United States have shown that irAEs can be a good prognostic sign, suggesting these therapies are working. Rheumatology is faced with new problems as onco-immunotherapies may induce new chronic diseases in multiple different forms secondary to the treatment.